重视胆汁淤积性肝病的诊断和药物治疗

doi:10.3969/j.issn.1672-5069.2016.06.001

Abstract

Shi Yiwen，You Hong.. Diagnosis and medical treatment of patitents with cholestatic liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 641-643.

[1] 中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识（2015）. 中华肝脏病杂志，2015，23:924-933.
[2] EASL Clinical Practice Guidelines:management of cholestatic liver diseases. J Hepatol，2009，51:237-267.
[3] Zhang DK，Chen M，Liu Y，et al. Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis:A preliminary study. Clin Radiol，2014，69:836-840.
[4] Lammers WJ，Hirschfield GM，Corpechot C，et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology，2015，149:1804-1812.e1804.
[5] Carbone M，Sharp SJ，Flack S，et al. The UK-PBC risk scores:Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology，2016，63:930-950.
[6] Zhang LN，Shi TY，Shi XH，et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis:results of a 14-year cohort study. Hepatology，2013，58:264-272.
[7] Mitchell SA，Bansi DS，Hunt N，et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology，2001，121:900-907.
[8] Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis:throwing the urso out with the bathwater Hepatology，2009，50:671-673.
[9] Sinakos E，Marschall HU，Kowdley KV，et al. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis:Relation to disease progression. Hepatology，2010，52:197-203.
[10] Trauner M，Halilbasic E，Kazemi-Shirazi L，et al. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. Dig Dis，2014，32:631-636.
[11] Neuschwander-Tetri BA，Loomba R，Sanyal AJ，et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic，non-alcoholic steatohepatitis（FLINT）:a multicentre，randomised，placebo-controlled trial. Lancet， 2015，385:956-965.
[12] Hirschfield GM，Mason A，Luketic V，et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology， 2015，148:751-761.e758.
[13] Nevens F，Andreone P，Mazzella G，et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med，2016，375:631-643.
[14] Cheung AC， Lapointe-Shaw L，Kowgier M，et al. Combined ursodeoxycholic acid（UDCA） and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther，2016，43:283-293.
[15] Levy C，Peter JA，Nelson DR，et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther，2011，33:235-242.
[16] Zhang Y，Li S，He L，et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis. Drug Des Devel Ther，2015，9:2757-2766.
[17] Hegade VS，Khanna A，Walker LJ，et al. Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score. Dig Dis Sci，2016，[ahead of print].
[18] Hosonuma K，Sato K，Yamazaki Y，et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol，2015，110:423-431.

Diagnosis and medical treatment of patitents with cholestatic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[2]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[3]	Gao Zhiliang, Zhu Xiang. How to achieve the clinical cure of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 305-308.
[4]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[5]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[6]	Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.
[7]	Zhao Xiaofei, Lin Dongdong, Li Ning, Zang Yunjin, Guo Qingliang, Wu Juanshan. Application of warfarin in dealing with portal vein thrombosis in patients with liver cirrhosis after splenectomy and devascularization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 240-243.
[8]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[9]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[10]	Li Yue, Ding Huiguo.. Current diagnosis and treatment of chylous ascites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 665-668.
[11]	Cao Fenghua, Jing Jisheng, Zhao Wei, et al.. Clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 729-732.
[12]	Cao Haixia, Fan Jiangao. Brief introduction of ESPGHAN recommendation for the diagnosis and treatment of children with Wilson's disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 502-504.
[13]	Chen Xiaoqing, Wang Yinchun. Etiology and treatment of intrahepatic cholestatic liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 163-165.
[14]	Wang Yanxin, Yu Hongwei, Zhu Yueke. Nutritional assessment and treatment in patients with chronic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 317-320.
[15]	He Zhiying, Zhao Xinyan. Liver histopathology in dealing with patients with unknown causes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 10-13.